ZAI Lab (Shanghai) Co., Ltd.
- Country
- 🇨🇳China
- Ownership
- Private, Subsidiary
- Established
- 2014-01-06
- Employees
- -
- Market Cap
- -
- Website
- http://www.zailaboratory.com
Clinical Trials
19
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (19 trials with phase data)• Click on a phase to view related trials
A Study of ZL-1310 in Participants With Selected Solid Tumors
- First Posted Date
- 2025-03-20
- Last Posted Date
- 2025-06-11
- Lead Sponsor
- Zai Lab (Shanghai) Co., Ltd.
- Target Recruit Count
- 86
- Registration Number
- NCT06885281
- Locations
- 🇺🇸
Zai Lab Site 2001, San Francisco, California, United States
🇺🇸Zai Lab Site 2002, New York, New York, United States
🇺🇸Zai Lab Site 2024, Cleveland, Ohio, United States
An Open-label, Multicenter Study of ZL-1310 in Subjects With Small Cell Lung Cancer
- First Posted Date
- 2023-12-21
- Last Posted Date
- 2025-06-18
- Lead Sponsor
- Zai Lab (Shanghai) Co., Ltd.
- Target Recruit Count
- 85
- Registration Number
- NCT06179069
- Locations
- 🇪🇸
Zai Lab Site 8007, Barcelona, Spain
🇪🇸Zai Lab Site 8009, Madrid, Spain
🇪🇸Zai Lab Site 8008, Málaga, Spain
To Evaluate Pharmacokinetics of Tisotumab Vedotin in Chinese Subjects With Metastatic or Recurrent Solid Malignancies
- Conditions
- Solid Malignancies
- First Posted Date
- 2023-05-19
- Last Posted Date
- 2023-11-27
- Lead Sponsor
- Zai Lab (Shanghai) Co., Ltd.
- Target Recruit Count
- 19
- Registration Number
- NCT05866354
- Locations
- 🇨🇳
Jinan Central Hospital, Jinan, Shangdong, China
The Clinical Trial to Evaluate the Pharmacokinetics and Safety of MRTX849 in Patients With Advanced Solid Tumors
- First Posted Date
- 2022-03-03
- Last Posted Date
- 2023-02-27
- Lead Sponsor
- Zai Lab (Shanghai) Co., Ltd.
- Target Recruit Count
- 22
- Registration Number
- NCT05263986
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Chongqing University Cancer Hospital, Chongqing, Chongqing, China
🇨🇳Henan Cancer Hospital, Zhengzhou, Henan, China
A Study to Evaluate the Safety and Efficacy of MGD013 in Patients With Melanoma
- Conditions
- Untreated Mucosal or Acral Lentiginous MelanomaUnresectable, Recurrent or Metastatic Melanoma
- Interventions
- First Posted Date
- 2020-12-04
- Last Posted Date
- 2024-01-29
- Lead Sponsor
- Zai Lab (Shanghai) Co., Ltd.
- Target Recruit Count
- 92
- Registration Number
- NCT04653038
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Fujian Cancer Hospital, Fuzhou, Fujian, China
🇨🇳Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China
- Prev
- 1
- 2
- 3
- 4
- Next